SUPPLEMENTARY TABLES

Trial name/identifier	**Trial design**	**Neoadjuvant trial intervention**	**Primary endpoint(s)**
NEOMUN, NCT03197467	Phase 2, single-arm, n=30 Stage 2-3A	Pembrolizumab (2 cycles)	Safety, feasibility, tumour response (RECIST, PET and Junker criteria)
PRINCEPS, NCT02994576	Phase 2, single-arm, n=60 Stage 1B-3A (non-N2)	Atezolizumab (1 cycle)	Rate free of major toxicities or morbidities
NCT03732664	Phase 1, single arm, n=40 Stage 1A-3A	Nivolumab (3 cycles)	Safety and AE rate
IoNESCO, NCT03030131	Phase 2, single arm, n=81 Stage 1B-2B	Durvalumab (3 cycles)	R0 resection rate
TOP 1501, NCT02818920	Phase 2, single-arm, n=35 Stage 1B-3A	Pembrolizumab (2 cycles) + adjuvant pembrolizumab	Surgical feasibility rate
NEOpredict, NCT04205552	Phase 2, two-arm, randomized, open-label, n=60 Stage 1-3A	Nivolumab ± relatlimab (2 cycles)	Feasibility
POPCORN, ACTRN	Phase 1B/2, two-arm,	Nivolumab ± denosumab (2 cycles)	Pharmacodynamic correlates of

12618001121257	randomized, open-label, n=30 Stage 1-3A		neoadjuvant therapy
NADIM-II, NCT03838159	Phase 2, two-arm, randomized, open-label, n=90 Potentially resectable stage 3A-B	Platinum-doublet NACT ± neoadjuvant/adjuvant nivolumab	pCR
NCT03081689	Phase 2, single-arm, n=46 Stage 3A (N2)	Platinum-doublet NACT + neoadjuvant/adjuvant nivolumab (1 neoadjuvant cycle)	PFS
NCT02572843	Phase 2, single arm, n=68 Stage 3A (N2)	Platinum-doublet NACT + neoadjuvant/adjuvant durvalumab (2 neoadjuvant cycles)	EFS
NCT03237377	Phase 2, single-arm, n=32 Stage 3A	Durvalumab + thoracic RT (2 cycles, 45Gy) Possibility of tremelimumab expansion arm	Toxicity, feasibility
NCT03871153	Phase 2, single arm, n=25 Stage 3 (N2)	Chemoimmunoradio-therapy (platinum doublet + durvalumab + thoracic RT) (3 cycles, 45-61.2Gy) + adjuvant durvalumab	pCR

Supplementary Table 1. Ongoing phase 1-2 trials employing neoadjuvant immunotherapy in non-small cell lung cancer. NACT (neoadjuvant chemotherapy), RT

(radiotherapy), Gy (Gray), RECIST (Response Evaluation Criteria in Solid Tumors), PET (positron-emission tomography), AE (adverse events), pCR (pathological complete response), PFS (progression-free survival), EFS (event-free survival).

Trial name/identifier	**Trial design**	**Adjuvant trial intervention**	**Primary endpoint(s)**
BR.31, NCT02273375	Phase 3, two-arm, randomized, double-blinded, n=1,360	Durvalumab vs placebo for up to 12 months in addition to standard-of-care adjuvant chemotherapy and/or radiotherapy in patients with resected stage 1B (primary ≥ 4cm) – 3A NSCLC	DFS in PD-L1 positive patients, DFS in all patients
PEARLS (KEYNOTE-091), NCT02504372	Phase 3, two-arm, randomized, double-blinded, n=1,080	Pembrolizumab vs placebo for up to 12 months in patients with resected stage 1B (primary ≥ 4cm) – 3A NSCLC	DFS
IMpower010, NCT02486718	Phase 3, two-arm, randomized, open-label, n=1,280	Atezolizumab in intervention group for up to 12 months following completion of adjuvant cisplatin-based chemotherapy in patients with resected stage 1B (primary ≥ 4cm) – 3A NSCLC	DFS in PD-L1-selected populations within various subgroups (stage 2-3A subpopulation, stage 2-3A participants, and ITT population)
ANVIL, NCT02595944	Phase 3, two-arm, randomized, open-label, n=903	Nivolumab in intervention group for up to 12 months following completion of any adjuvant chemotherapy or radiotherapy in patients with resected stage 1B	DFS and OS, each stratified by PD-L1 expression

		(primary ≥ 4cm) – 3A NSCLC not harbouring EGFR mutations (exon 19 deletion or exon 21 L858R) or ALK rearrangement	

Supplementary Table 2. Phase 3 trials of adjuvant immunotherapy in resected non-small cell lung cancer (NSCLC). Note: in all trials, UICC version 7 staging was used, where stage 3A would now correlate with 3B in the case of pT3N2M0 disease, although these patients were still included. DFS, disease-free survival; PD-L1, programmed death-1-ligand 1; OS, overall survival; EGFR, epithelial growth factor receptor; ALK, anaplastic lymphoma kinase.